Scinai Immunotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.5%.

Top 20 shareholders own 41.47% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.3%	Daniel Stone	624,000	US$284.0k	0%	no data
11.9%	Armistice Capital LLC	518,315	US$235.9k	43%	0.01%
9.82%	Angels High Tech Investments Ltd	427,404	US$194.5k	0%	no data
5.07%	Sabby Management, LLC	220,663	US$100.4k	-9.92%	0.59%
0.12%	Rhumbline Advisers Ltd Partnership	5,314	US$2.4k	49.7%	no data
0.059%	Morgan Stanley, Investment Banking and Brokerage Investments	2,582	US$1.2k	13.2%	no data
0.049%	UBS Asset Management AG	2,117	US$963.5	157%	no data
0.032%	Geode Capital Management, LLC	1,381	US$628.4	3.06%	no data
0.024%	George Lowell	1,054	US$479.7	0%	no data
0.012%	Avner Rotman	514	US$233.9	0%	no data
0.0097%	Amundi Asset Management SAS	424	US$192.9	0%	no data
0.0077%	Adi Raviv	334	US$151.9	0%	no data
0.0046%	Main Street Group, Ltd	200	US$91.1	0%	no data
0.0038%	Morris Laster	167	US$76.1	0%	no data
0.0038%	Yael Margolin	167	US$76.1	0%	no data
0.0037%	Aspire Private Capital, LLC	160	US$72.9	0%	no data
0.0011%	Global Retirement Partners, LLC	50	US$22.8	0%	no data
0.00046%	Wells Fargo & Company, Securities and Brokerage Investments	20	US$9.1	0%	no data
0.00016%	Qube Research & Technologies Ltd	7	US$3.2	0%	no data
0.00009%	RBC Dominion Securities Inc., Asset Management Arm	4	US$1.8	0%	no data